… pieces and examined for EGFR status and again no EGFR mutation heterogeneity was
found. The authors concluded that heterogeneous distribution of EGFR mutations is extremely …

… in EGFR-positive disease. In this review, we overview the tumour heterogeneity of NSCLC
harbouring EGFR … subtypes of EGFR mutations determine different patterns of response to …

… Non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations
have mixed responses to tyrosine kinase inhibitors (TKIs). Intertumor heterogeneity in EGFR …

… heterogeneous subgroup of patients with EGFR mutations, with different sensitivity to first-
and second-generation EGFR TKIs, that accounts for approximately 10% of all EGFR … EGFR …

… mechanism underlying EGFR TKI … heterogeneity within NSCLC cells lines harboring EGFR
kinase domain mutations that give rise to divergent resistance mechanisms in response to …

… heterogeneous effects of different kinds of EGFR inhibitors along with the differential response
… sufficient to predict the efficacy of anti-EGFR antibodies or tyrosine kinase inhibitors in the …

… of EGFR or HER2, respectively. In this study, we investigated the effects of specific EGFR …
that had clinically achieved a partial response after dacomitinib treatment. We identified Gly770 …

… both intratumoral and intertumoral heterogeneity, as well as … -generation EGFR inhibitors
that block both activating EGFR … each elicit responses in approximately 60% of EGFR-mutant …

… heterogeneous genetic alterations in genes involved in EGFR signaling, which negatively
affect response to … Molecular heterogeneity has been recognized as pivotal in the evolution of …

Cancer molecular heterogeneity might explain the variable response of EGFR mutant lung
adenocarcinomas to tyrosine kinase inhibitors (TKIs). We assessed the mutational status of …